These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27796466)

  • 21. The regulation of gastric acid secretion - clinical perspectives.
    Waldum HL; Hauso Ø; Fossmark R
    Acta Physiol (Oxf); 2014 Feb; 210(2):239-56. PubMed ID: 24279703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.
    Boyce M; Thomsen L
    Scand J Gastroenterol; 2015 May; 50(5):550-9. PubMed ID: 25665655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.
    Webb DL; Rudholm-Feldreich T; Gillberg L; Halim MA; Theodorsson E; Sanger GJ; Campbell CA; Boyce M; Näslund E; Hellström PM
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):41-9. PubMed ID: 23179899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked increase in gastric acid secretory capacity after omeprazole treatment.
    Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
    Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.
    Gori G; Spinelli G; Spinelli C; Tuccori M; Blandizzi C; Del Tacca M
    Nat Rev Gastroenterol Hepatol; 2010 Nov; 7(11):642-6. PubMed ID: 20938461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential clinical indications for a CCK
    Boyce M; Lloyd KA; Pritchard DM
    Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
    Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
    Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
    Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study.
    Chen D; Zhao CM; Norlén P; Björkqvist M; Ding XQ; Kitano M; Håkanson R
    Cell Tissue Res; 2000 Jan; 299(1):81-95. PubMed ID: 10654072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
    Juul-Hansen P; Rydning A
    Scand J Gastroenterol; 2011 Apr; 46(4):398-405. PubMed ID: 21142586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
    Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
    Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cholecystokinin-B/gastrin receptor blockade suppresses the activity of rat stomach ECL cells.
    Ding XQ; Lindström E; Håkanson R
    Pharmacol Toxicol; 1997 Jul; 81(1):19-25. PubMed ID: 9258980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats.
    Konagaya T; Bernsand M; Norlén P; Håkanson R
    Br J Pharmacol; 2001 May; 133(1):37-42. PubMed ID: 11325792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.
    Reimer C; Søndergaard B; Hilsted L; Bytzer P
    Gastroenterology; 2009 Jul; 137(1):80-7, 87.e1. PubMed ID: 19362552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation.
    Kidd M; Modlin IM; Black JW; Boyce M; Culler M
    Regul Pept; 2007 Oct; 143(1-3):109-17. PubMed ID: 17531331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment.
    Sagatun L; Mjønes P; Jianu CS; Boyce M; Waldum HL; Fossmark R
    Eur J Gastroenterol Hepatol; 2016 Nov; 28(11):1345-1352. PubMed ID: 27682220
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.
    Niklasson A; Lindström L; Simrén M; Lindberg G; Björnsson E
    Am J Gastroenterol; 2010 Jul; 105(7):1531-7. PubMed ID: 20332770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia.
    Robinson M
    Aliment Pharmacol Ther; 1999 Oct; 13 Suppl 5():5-10. PubMed ID: 10555603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrin effects on isolated rat enterochromaffin-like cells following long-term hypergastrinaemia in vivo.
    Andersson N; Rhedin M; Peteri-Brunbäck B; Andersson K; Cabero JL
    Biochim Biophys Acta; 1999 Sep; 1451(2-3):297-304. PubMed ID: 10556584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.